Education
About Us
Working with TipRanks
Follow Us
Journey Medical Corp (DERM)
NASDAQ:DERM
DERM Stock Chart & Stats
$8.17
-$0.02(-0.58%)
At close: 4:00 PM EST
$8.17
-$0.02(-0.58%)
Day’s Range― - ―
52-Week Range$4.97 - $9.56
Previous CloseN/A
Volume25.59K
Average Volume (3M)122.30K
Market Cap
$271.71M
Enterprise Value$186.82M
Total Cash (Recent Filing)$24.95M
Total Debt (Recent Filing)$25.30M
Price to Earnings (P/E)―
Beta0.23
Next Earnings
Mar 19, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding27,256,588
10 Day Avg. Volume115,474
30 Day Avg. Volume122,297
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)3.98
Price to Sales (P/S)1.42
P/FCF Ratio-8.75
Enterprise Value/Market Cap0.69
Enterprise Value/Revenue3.15
Enterprise Value/Gross Profit4.60
Enterprise Value/Ebitda-264.25
Forecast
1Y Price Target
$13.00Price Target Upside59.12% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.25
Revenue Forecast (FY)$100.73M
Bulls Say, Bears Say
Bulls Say
Successful Commercial Launch Of AmroziA rapidly scaling new product demonstrates durable commercial strength: Amrozi’s strong prescription growth and material revenue contribution indicate meaningful prescriber adoption and a pathway to rebuild top-line scale, diversifying reliance away from legacy products over coming quarters.
Improving Profitability TrajectoryShift to positive adjusted EBITDA signals improving operating leverage and expense discipline. If sustained, this enhances cash generation potential, reduces cadence of external funding needs, and underpins reinvestment in marketing and pipeline over the medium term.
Marked Reduction In LeverageSignificant debt paydown materially lowers financial risk and interest burden, preserving balance sheet flexibility for commercialization and working capital. A lighter leverage profile supports resilience during market access execution and potential M&A or licensing opportunities.
Bears Say
Material Historical Revenue DeclineA large revenue contraction erodes scale, undermines fixed-cost absorption and competitive positioning. Recovering sustainable growth requires sustained new product traction and market access gains; otherwise structural margin pressure and constrained reinvestment capacity persist.
Negative Operating And Free Cash FlowPersistent cash burn weakens liquidity and forces reliance on financing or equity, limiting strategic optionality. Structural negative OCF constrains the company’s ability to scale commercial activities, fund launches, or absorb payer pressure without recurring external capital.
Exposure To Generics And Payor Access DynamicsGenerics and slow formulary adoption create structural revenue erosion and pricing pressure for legacy lines. Dependence on co-pay assistance is a non-scalable mitigation; prolonged payer access lag or reduced subsidy effectiveness can materially limit durable revenue and margin recovery.
Journey Medical Corp News
DERM FAQ
What was Journey Medical Corp’s price range in the past 12 months?
Journey Medical Corp lowest stock price was $4.97 and its highest was $9.55 in the past 12 months.
What is Journey Medical Corp’s market cap?
Journey Medical Corp’s market cap is $271.71M.
When is Journey Medical Corp’s upcoming earnings report date?
Journey Medical Corp’s upcoming earnings report date is Mar 19, 2026 which is in 16 days.
How were Journey Medical Corp’s earnings last quarter?
Journey Medical Corp released its earnings results on Nov 12, 2025. The company reported -$0.09 earnings per share for the quarter, missing the consensus estimate of -$0.048 by -$0.042.
Is Journey Medical Corp overvalued?
According to Wall Street analysts Journey Medical Corp’s price is currently Undervalued.
Does Journey Medical Corp pay dividends?
Journey Medical Corp does not currently pay dividends.
What is Journey Medical Corp’s EPS estimate?
Journey Medical Corp’s EPS estimate is -0.05.
How many shares outstanding does Journey Medical Corp have?
Journey Medical Corp has 27,256,588 shares outstanding.
What happened to Journey Medical Corp’s price movement after its last earnings report?
Journey Medical Corp reported an EPS of -$0.09 in its last earnings report, missing expectations of -$0.048. Following the earnings report the stock price went down -15.308%.
Which hedge fund is a major shareholder of Journey Medical Corp?
Currently, no hedge funds are holding shares in DERM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Journey Medical Corp Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.00 (59.12% Upside)
$13.00 (59.12% Upside)
Blogger Sentiment
Bullish
DERM Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 12.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 3.8%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
46.41%
12-Months-Change
Fundamentals
Return on Equity
-47.05%
Trailing 12-Months
Asset Growth
33.02%
Trailing 12-Months
Company Description
Journey Medical Corp
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream and solution. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
DERM Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment overall, driven by strong revenue growth and successful launch metrics for Amrozi. However, there are challenges such as declining legacy product revenues and reliance on co-pay assistance programs due to generic competition and slower formulary adoption, which are being addressed through strategic initiatives.View all DERM earnings summariesDERM Stock 12 Month Forecast
Average Price Target
$13.00
▲(59.12% Upside)
Technical Analysis
Talphera
―
Assertio Therapeutics
―
Cumberland Pharmaceuticals
―
China SXT Pharmaceuticals
―
Alpha Teknova
―
Ownership Overview
14.69% Insiders
6.44% Mutual Funds
25.45% Other Institutional Investors
49.11% Public Companies and
Individual Investors